Predictors of Androgen Status Decline in Middle-Aged Men

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age35-59
SponsorAndijan State Medical Institute

About this trial

Age-related decrease in testosterone levels in men is associated with multiple metabolic, functional and psychosocial consequences. Early identification of modifiable factors associated with decreased testosterone levels may contribute to improved prevention of androgen deficiency and related health conditions.

This population-based analytical cross-sectional observational study aims to investigate anthropometric, functional and lifestyle-related factors associated with decreased total testosterone levels in middle-aged men. Approximately 600 men aged 35-59 years residing in the Andijan region of Uzbekistan will be recruited.

Participants will undergo comprehensive assessment including anthropometric measurements, functional performance tests, standardized questionnaires and laboratory determination of serum total testosterone levels. Anthropometric variables will include body mass index, waist circumference, hip circumference, waist-to-hip ratio and waist-to-height ratio. Functional status will be assessed using hand-grip strength, five-times chair-stand test, 4-meter walk test, balance assessment and the six-minute walk test. Lifestyle-related factors including physical activity, sleep quality, dietary habits, smoking, alcohol consumption and psychoemotional status will be evaluated using validated questionnaires.

The study aims to identify determinants of decreased testosterone levels and develop a predictive model for early identification of androgen deficiency in middle-aged men.

Eligibility criteria

Qualifiers

Men aged 35-59 years

Permanent residence in the Andijan region of Uzbekistan

Ability to undergo anthropometric measurements and functional performance tests

Ability to complete study questionnaires

Disqualifiers

Previously diagnosed hypogonadism requiring hormonal therapy

Current testosterone replacement therapy or other medications affecting androgen status

Severe cardiovascular, hepatic or renal diseases in the stage of decompensation

Acute infectious or inflammatory diseases at the time of examination

Trial design

Treatments tested in this trial

  • Observational Assessment

Treatment groups

600 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Andijan State Medical Institute

Lead sponsor

Tashkent Medical Academy

Collaborator